secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001367644-26-000059
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 revenue $156.1M (-30% YoY); net income slumps 90%; guidance raised on adjusted EBITDA
--------------------------------------------------------------------------------

- Revenue $156.1M vs $222.2M in Q1 2025; net income $6.8M ($0.07 EPS) vs $68.0M ($1.19 EPS).
- Smallpox MCM revenue down 40% to $64.2M; Anthrax MCM down 55% to $21.6M.
- Adjusted EBITDA $35.6M (23% margin) vs $79.1M (36% margin) in Q1 2025.
- FY 2026 adjusted net income guidance raised to $45-65M (from $25-45M); FY 2026 adjusted EBITDA guidance raised to $155-175M (from $135-155M).
- Completed debt refinancing with $150M term loan; secured over $200M in new U.S./Canada government contracts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/0001367644-26-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/ebs-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001367644-26-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer